Sabreen Saleem Abd Alkreem Alsaqi (1)
General Background: Urinary bladder cancer is among the most prevalent malignancies worldwide, with its progression strongly influenced by clinicopathological characteristics. Specific Background: Despite extensive documentation of urothelial carcinoma behavior, variations in tissue morphology and their clinical correlations remain insufficiently clarified in regional populations. Knowledge Gap: Limited data exist regarding how histopathological patterns relate to tumor grade, stage, and patient demographics in Iraqi cohorts. Aim: This study examined the key pathological alterations in 50 bladder cancer patients to determine the association between tissue characteristics, tumor aggressiveness, and clinical outcomes. Results: High-grade tumors were predominant (80%), with most cases invading the deep muscle (78%). Men were disproportionately affected, and smoking emerged as a major risk factor. A significant correlation was observed between patient age and both tumor grade and stage, indicating that older individuals tend to present with more advanced disease. Novelty: The study highlights distinct high-grade T1 variants that may offer additional prognostic value, emphasizing heterogeneity within early-stage tumors. Implications: These findings underscore the need for improved risk-stratification strategies, earlier detection, and larger prospective studies to refine diagnostic and management protocols for bladder carcinoma.|Highlight :
The study shows most cases present as high-grade and advanced stage.
Smoking and chemical exposure appear as major contributing risks.
Tumor grade and invasion depth remain key indicators for diagnosis and management.
Keywords : Bladder Cancer, Papillary Carcinomas, Histopathological Features, Tumor Grade, Age
L. Dyrskjot et al., “Bladder Cancer,” Nature Reviews Disease Primers, vol. 9, p. 58, 2023, doi: 10.1038/s41572-023-00468-9.
G. Li, S. Wu, J. Liu, K. Wang, X. Chen, and H. Liu, “Narrow Bandgap Schottky Heterojunction Sonosensitizer With High Electron-Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer,” Advanced Materials, vol. 36, 2024, Art. no. e2401252, doi: 10.1002/adma.202401252.
Y. Li et al., “Recent Advances in Diagnosing and Treating Post-Prostatectomy Urinary Incontinence,” Annals of Surgical Oncology, vol. 31, no. 12, pp. 8444–8459, 2024.
V. Bilim et al., “Advanced Bladder Cancer: Changing the Treatment Landscape,” Journal of Personalized Medicine, vol. 12, p. 1745, 2022.
G. Gluck et al., “Comparative Study of Conventional Urothelial Carcinoma, Squamous Differentiation Carcinoma and Pure Squamous Carcinoma in Patients With Invasive Bladder Tumors,” Journal of Medicine and Life, vol. 7, pp. 211–216, 2014.
F. Bray et al., “Cancer Incidence in Five Continents: Inclusion Criteria, Highlights From Volume X and the Global Status of Cancer Registration,” International Journal of Cancer, vol. 137, no. 9, pp. 2060–2071, 2015.
A. Richters, K. K. Aben, and L. A. Kiemeney, “The Global Burden of Urinary Bladder Cancer: An Update,” World Journal of Urology, vol. 38, no. 8, pp. 1895–1904, 2020.
M. Burger et al., “Epidemiology and Risk Factors of Urothelial Bladder Cancer,” European Urology, vol. 63, no. 2, pp. 234–241, 2013.
H. R. Kourie et al., “Genetic Polymorphisms Involved in Bladder Cancer: A Global Review,” Oncology Reviews, vol. 17, p. 10603, 2023, doi: 10.3389/or.2023.10603.
O. Sanli et al., “Bladder Cancer,” Nature Reviews Disease Primers, vol. 3, p. 17022, 2017.
K. P. Ratnam, S. Jagadeeswari, and S. Krishna Kumari, “Malignant Melanoma of Uterine Cervix in a Young Female,” International Journal of Scientific Research, vol. 8, no. 11, pp. 1–2, 2019.
M. M. Al-Thuwaini, S. H. Enayah, M. A. Alwzy, and A. A. Hafeh, “Assessment of the Incidence of Transitional Cell Carcinoma (TCC) of the Bladder Cancer,” International Journal of Pharmaceutical and Clinical Research, vol. 10, no. 2, pp. 356–360, 2019.
T. J. Kim, K. S. Cho, and K. C. Koo, “Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review,” Cancers, vol. 12, no. 1, p. 192, 2020.
N. D. Freedman et al., “Association Between Smoking and Risk of Bladder Cancer Among Men and Women,” JAMA, vol. 306, pp. 737–745, 2011.
G. Li et al., “Squamous Differentiation in Patients With Superficial Bladder Urothelial Carcinoma Is Associated With High Risk of Recurrence and Poor Survival,” BMC Cancer, vol. 17, p. 1, 2017.
T. Van der Kwast et al., “International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma,” European Urology Focus, 2021.
Y. Liu, M. M. Bui, and B. Xu, “Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis,” Journal of the Moffitt Cancer Center, vol. 24, no. 1, pp. 78–82, 2017.
M. Babjuk et al., “EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2013,” European Urology, vol. 64, no. 4, pp. 639–653, 2013.
E. P. Shrestha and K. Karmacharya, “Profiles of Histopathological Lesions of Urinary Bladder: A Five Years Study,” Journal of Pathology of Nepal, vol. 6, no. 12, pp. 1001–1004, 2016.
Z. M. Akhtar et al., “Histopathological Spectrum of Urinary Bladder Cancer—Experience From a Tertiary Care Hospital,” Journal of Fatima Jinnah Medical University, vol. 12, no. 3, pp. 119–123, 2018.
A. D. Mally et al., “Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder,” Clinical Genitourinary Cancer, vol. 14, pp. 30199–30204, 2017.
R. P. Samo et al., “Urothelial Carcinoma and Its Association With Age and Gender,” The Professional Medical Journal, vol. 26, no. 10, pp. 1719–1723, 2019.